PHARMAnetwork

CordenPharma expands global capacity, investing in key platforms to deliver fully-integrated solutions across multiple therapeutic modalities, from drug substance to drug product and packaging. CordenPharma understands today’s pharma market demands and is investing in key technology platforms - Small Molecules & Highly Potent Drug Substance and Drug Products, Injectables, Peptides, Lipids & LNPs - to provide customers with true end-to-end support.

The CDMO sector is no longer simply a hierarchy of margins or multiples. It is now organized around distinct industrial trajectories, where the ability to invest, integrate, and scale up becomes as crucial as immediate profitability. Beyond the indicators, the ability of CDMOs to articulate productivity, investment and positioning in their market determines their true value creation.

PHARMAnetwork: Independent strategic media on CDMOs & contract pharmaceutical manufacturing Founded in 2008, PHARMAnetwork magazine provides independent editorial coverage and strategic insight into pharmaceutical manufacturing, contract development and manufacturing (CDMO), and the evolving dynamics of global outsourcing.

The current geopolitical situation, particularly the closure of strategic shipping routes, raises questions about the resulting supply tensions and their impact on the relationships between subcontractors and prime contractors.

PHARMAnetwork is a strategic media platform dedicated to pharmaceutical manufacturing, outsourcing and CDMO markets. We connect advertisers with a highly targeted international audience of senior decision-makers across Europe and the United States. PHARMAnetwork reaches CEOs, COOs, industrial directors, technical leaders, investors and regulatory specialists actively involved in pharmaceutical manufacturing and contract development.

Terms and Conditions of Use This website is owned and operated by PHARMAnetwork Ltd., a company registered in England and Wales under company number 10807134, whose registered office is at: Becket House, C/O CCFGB 1 Lambeth Palace Road London, England, SE1 7EU United Kingdom Section 1 – Acceptance of Terms 1.1 Please read these Terms and Conditions carefully. By accessing and using this website, you agree to be legally bound by these Terms.

LSX Nordic Congress Copenhagen, Denmark CPHI North America Philadelphia, USA CPHI China Shanghai, China The calendar is updated from the information we receive from the event organizing companies and from our partners. Last updated: April 2026

Since the beginning of the year, the CDMO sector has entered a new cycle of accelerated capital deployment, reflecting both increased customer demand and improved financial market confidence. The scale of these investments is significant. Investments in sterile injectables, peptides, and advanced therapies are not only reshaping the industrial footprint but are also transforming the financial dynamics of the sector.

Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.

PCI Pharma Services announced on July 14, 2025 that it has received a strategic investment co-led by Bain Capital and Kohlberg, the current lead investor, and supported by a significant reinvestment from Mubadala Investment Company ("Mubadala"). Partners Group will also continue to support the company with a minority stake.